Hyderabad-based Bharat Biotech has announced that iNCOVACC®️ (BBV154), is scheduled to be introduced in the country as a booster dose shortly. Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC®️.
The vaccine is now available on CoWin, priced at Rs 800 for private markets and priced at Rs 325 for supplies to Govt of Indian and State Governments.
iNCOVACC®️ has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.
As a needleless vaccination, Bharat Biotech's iNCOVACC®️ will be India's first such booster dose. India will now have more options when it comes to third doses or precautionary doses.
Despite the lack of demand for COVID-19 vaccines, Bharat Biotech continued product development in intranasal vaccines, to be well-prepared with platform technologies for future infectious diseases.
iNCOVACC®️ is stable at 2-8°C for easy storage and distribution. Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including Gujarat, Karnataka, Maharashtra, and Telangana, with operations pan India.
